Applied Therapeutics, Inc.

NasdaqGM:APLT Stok Raporu

Piyasa değeri: US$1.1b

Applied Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Applied Therapeutics kazanç ve gelirinin sırasıyla yıllık 42.1% ve 59% oranında artması tahmin edilirken, EPS'nin yıllık 59.3% oranında büyümesi bekleniyor.

Anahtar bilgiler

42.1%

Kazanç büyüme oranı

59.3%

EPS büyüme oranı

Biotechs kazanç büyümesi28.4%
Gelir büyüme oranı59.0%
Gelecekteki özkaynak getirisin/a
Analist kapsamı

Low

Son güncelleme20 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Nov 15
Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review

Sep 18

Applied Therapeutics: Pushing Towards FDA Approval

Sep 04

We're Hopeful That Applied Therapeutics (NASDAQ:APLT) Will Use Its Cash Wisely

Aug 01
We're Hopeful That Applied Therapeutics (NASDAQ:APLT) Will Use Its Cash Wisely

Applied Therapeutics: Navigating Challenges In ARI Development For Rare Diseases

May 28

Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible

Feb 16

Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

Feb 16
Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

Nov 13
Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

Aug 11
We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

May 19
We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock

Jan 19

Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

Nov 11
Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Aug 13
Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Applied Therapeutics trades higher on FDA Fast Track designation for rare metabolic disorder

Jun 17

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

May 15
Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)

Feb 26
Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)

How Much Of Applied Therapeutics, Inc. (NASDAQ:APLT) Do Insiders Own?

Feb 18
How Much Of Applied Therapeutics, Inc. (NASDAQ:APLT) Do Insiders Own?

Applied Therapeutics to resume galactosemia study for AT-007

Feb 02

Applied Therapeutics, Inc. (NASDAQ:APLT) Insiders Have Been Selling

Nov 24
Applied Therapeutics, Inc. (NASDAQ:APLT) Insiders Have Been Selling

Applied Therapeutics EPS misses by $0.21

Nov 12

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGM:APLT - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/2026155-73N/AN/A3
12/31/202557-88N/AN/A4
12/31/20241-180N/AN/A3
9/30/20240-187-82-82N/A
6/30/20240-161-73-73N/A
3/31/20240-194-67-67N/A
12/31/202310-120-55-55N/A
9/30/202311-97-54-54N/A
6/30/202311-73-59-59N/A
3/31/202311-70-61-61N/A
12/31/2022N/A-83-78-78N/A
9/30/2022N/A-95-89-89N/A
6/30/2022N/A-105-85-85N/A
3/31/2022N/A-105-93-93N/A
12/31/2021N/A-106-91-91N/A
9/30/2021N/A-102-87-87N/A
6/30/2021N/A-104-92-92N/A
3/31/2021N/A-106-82-82N/A
12/31/2020N/A-94-78-78N/A
9/30/2020N/A-88-68-68N/A
6/30/2020N/A-69-55-55N/A
3/31/2020N/A-49-48-48N/A
12/31/2019N/A-46-36-36N/A
9/30/2019N/A-35-30-30N/A
6/30/2019N/A-28-24-24N/A
3/31/2019N/A-23-17-17N/A
12/31/2018N/A-17-11-11N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: APLT önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: APLT önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: APLT önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: APLT şirketinin gelirinin (yıllık 59% ) US pazarından (yıllık 9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: APLT şirketinin gelirinin (yıllık 59% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: APLT 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok


Büyüyen şirketleri keşfedin